Thirty-six patients (17%) achieved a minor response
, defined as a greater than 50% decrease in transfusion dependence according to IWG criteria.
Importantly, responses have also been sustained; patients achieving partial or minor responses
stayed on therapy for a median treatment duration of 240 days, or approximately 8 months, and the median duration of response was 7.
One 4th-line NSCLC patient, a 77-year old man with metastatic disease, had a minor response
per the treating physician and a best response (per RECIST) of stable disease for 43 weeks.
In the seven advanced solid tumor patients with brain metastases who received ANG1005 at a dose of >300mg/m2, five patients experienced an objective response, including one partial response, two minor responses
and two had their disease stabilize;
Of 39 evaluable patients, ten (26%) achieved partial or minor responses
and an additional 16 (41%) achieved stable disease.
Despite advanced disease in the majority of patients, 2 patients experienced stable disease for at least 6 months and a minor response
was seen in a patient with pancreatic cancer.
REOLYSIN Dose Primary Tumour TCID(50) Cycles Best Response Breast 1x10(10) 8 PR CR in liver Gastric 3x10(10) 8* PR 32% reduction in lymph nodes Mesothelioma 1x10(10) 6 Minor response
23% reduction in lymph nodes Prostate 3x10(9) 6 SD on scans 30% reduction in PSA Squamous Cell 3x10(9) 3 Minor response
Carcinoma 26% reduction in Head and Neck lymph node Unknown 3x10(9) 6 SD Pancreas 3x10(10) 6* SD Prostate 3x10(10) 5* SD Prostate 3x10(10) 5 SD Melanoma 1x10(10) 4 SD Pancreas 3x10(10) 2 SD, but progressed clinically * patients still on study.
Of the 33 patients analyzed for response, 1 patient with ovarian cancer experienced a minor response
(29% decrease in tumor mass) and there were 15 patients with stable disease, 15 patients with progressive disease and 2 patients were not evaluable.
In addition, 1 minor response
(21% tumor reduction with a duration of 43 months) was observed and only 1 of the 19 evaluable patients showed disease progression on therapy.